Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika: molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu
The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel
MetadataShow full item record
Multi-drug resistance (MDR) is a major obstacle to successful cancer treatment.The efficacy of paclitaxel (PTX) is often limited by appearance of drug resistance. The aim ofthis study was to explore molecular and phenotypic alterations during development of MDRinduced by PTX in human colon carcinoma (DLD1) and glioblastoma (U87) cell lines. Wealso tested the usefulness of developed MDR models in the evaluation of four anti-canceragents.Continuous treatment with PTX led to the development of MDR in both testedcancer cell lines that became resistant to structurally and functionally unrelatedchemotherapeutics. After confirmation of the cross-resistance in newly established DLD1-TxRand U87-TxR, we analyzed the mRNA expression of membrane transporters involved inMDR. The cells had increased levels of mdr1 gene expression, while mrp1 was decreased.Over-expression of P-glycoprotein (P-gp), coded by mdr1, was observed in both MDR cancercell lines. Flow cytometry analyzes showed that the accumulation of P-gp substrates(rhodamine 123 and doxorubicin) in DLD1-TxR and U87-TxR was significantly lowercompared to DLD1 and U87, respectively. The significant depletion of gst-π gene expressionand glutathione (GSH) concentration was observed in U87-TxR. Vascular Endothelial GrowthFactor (VEGF) secretion was inhibited by single PTX treatment of colon cancer and incontinuous treatment of glioblastoma cell lines. The analysis of cell cycle kinetics revealedextensive cell death in colon cancer cells that were accumulated in subG0 phase after PTXtreatment, while glioblastoma cells died through interphase (G1, S or G2). The MDR cancercell lines acquired novel structural or numerical chromosomal aberrations. Polyploidyreduction was observed after development of MDR in U87-TxR. Losses of 6q in both resistantcancer cell lines and inactivation of p53 in U87-TxR and PTEN in DLD1-TxR were alsorevealed.We evaluated the anti-cancer activities and MDR reversal potential of the Aktinhibitor (GSK690693), the Ras inhibitor (Tipifarnib) and two P-gp inhibitors (jatrophanediterpenoids Euphodendrophane H-Euph H and Euphodendrophane S -Euph S). Their effectsvary due to the cell-type differences, existence of MDR phenotype or tumor suppressors’alterations. Tipifarnib, Euph H and S, significantly sensitized MDR cancer cells to PTX.
Keywords:Multi-drug resistance (MDR); Paclitaxel (PTX); Colon cancer; Glioblastoma; P-glycoprotein; Anti-cancer agents
Source:University of Belgrade, Faculty of Belgrade, 2013, 1-110
- Identification of predictive molecular markers for cancer progression, response to therapy and disease outcome (RS-41031)
- Identifikacija specifičnih gena za terapiju kancera (RS-143009)